Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis

Journal of the American Academy of Dermatology

Volumn 60, Issue 2, 2009, Pages 225-230

  Chen, Yi Ju ^a,b,c   Shen, Jui Lung ^a   Wu, Chun Ying ^a   Chang, Yun Ting ^c,d   Chen, Chuan Mu ^b   Lee, Fang Yi ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OSTEOPONTIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE DISTRIBUTION; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MACROPHAGES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PSORIASIS; RISK FACTORS;

EID: 58149345016     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.09.046     Document Type: Article

References (44)

1. McDonald C.J. Cardiovascular disease in psoriasis. J Invest Dermatol 92 (1989) 646-647
2. Poikolainen K., Karvonen J., and Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 135 (1999) 1490-1493
3. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
4. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
5. Herron M.D., Hinckley M., Hoffman M.S., Paperfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
6. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
7. Cohen A.D., Gilutz H., Henkin Y., Zahger D., Shapiro J., Bonneh D.Y., et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 87 (2007) 506-509
8. Brown L.F., Berse B., Van de W.L., Papadopoulos-Sergiou A., Perruzzi C.A., Manseau E.J., et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3 (1992) 1169-1180
9. Butler W.T. The nature and significance of osteopontin. Connect Tissue Res 23 (1989) 123-136
10. Miyazaki Y., Setoguchi M., Yoshida S., Higuchi Y., Akizuki S., and Yamamoto S. The mouse osteopontin gene: expression in monocytic lineages and complete nucleotide sequence. J Biol Chem 265 (1990) 14432-14438
11. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., and Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 (1993) 1686-1696
12. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., and Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107 (2001) 1055-1061
13. Renkl A.C., Wussler J., Ahrens T., Thoma K., Kon S., Uede T., et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106 (2005) 946-955
14. Liaw L., Almeida M., Hart C.E., Schwartz S.M., and Giachelli C.M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 74 (1994) 214-224
15. Giachelli C.M., Liaw L., Murry C.E., Schwartz S.M., and Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 760 (1995) 109-126
16. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S., and Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 92 (1993) 2814-2820
17. Shanahan C.M., Cary N.R., Metcalfe J.C., and Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93 (1994) 2393-2402
18. Ohmori R., Momiyama Y., Taniguchi H., Takahashi R., Kusuhara M., Nakamura H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170 (2003) 333-337
19. Minoretti P., Falcone C., Calcagnino M., Emanuele E., Buzzi M.P., Coen E., et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 27 (2006) 802-807
20. Kurata M., Okura T., Watanabe S., Fukuoka T., and Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Colch) 111 (2006) 319-324
21. D'Alfonso S., Barizzone N., Giordano M., Chiocchetti A., Magnani C., Castelli L., et al. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52 (2005) 539-547
22. Caillier S., Barcellos L.F., Baranzini S.E., Swerdlin A., Lincoln R.R., Steinman L., Chu S.Y., Chen C.K., Chen C.M., et al. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun 4 (2003) 312-315
23. Xu A.P., Bai J., Lü J., Liang Y.Y., Li J.G., Lai D.Y., et al. Osteopontin gene polymorphism in association with systemic lupus erythematosus in Chinese patients. Chin Med J (Engl) 120 (2007) 2124-2128
24. Xu G., Sun W., He D., Wang L., Zheng W., Nie H., et al. Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32 (2005) 410-416
25. Urcelay E., Martinez A., Mas-Fontao A., Peris-Pertusa A., Pascual-Salcedo D., Balsa A., et al. Osteopontin gene polymorphisms in Spanish patients with rheumatoid arthritis. J Rheumatol 32 (2005) 405-409
26. Clark R.A., and Kupper T.S. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 116 (2006) 2084-2087
27. Stratis A., Pasparakis M., Rupec R.A., Markur D., Hartman K., Scharffetter-Kochanek K., et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 116 (2006) 2094-2104
28. Wang H., Peters T., Kess D., Sindrilaru A., Oreshkova T., Van Rooijen N., et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116 (2006) 2105-2114
29. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
30. Einhorn D., Reaven G.M., Cobin R.H., Ford E., Ganda O.P., Handelsman Y., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
31. Schottelius A.J., Moldawer L.L., Dinarello C.A., Asadullah K., Sterry W., and Edwards III C.K. Biology of tumor necrosis factor-alpha implications for psoriasis. Exp Dermatol 13 (2004) 193-222
32. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
33. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81 (1997) 627-635
34. Wakkee M., Thio H.B., Prens E.P., Sijbrands E.J., and Neumann H.A. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 190 (2007) 1-9
35. Malerba M., Gisondi P., Radaeli A., Sala R., Calzavara Pinton P.G., and Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 155 (2006) 1165-1169
36. Vanizor Kural B., Orem A., Cimşit G., Uydu H.A., Yandi Y.E., and Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 332 (2003) 23-30
37. Johnston A., Arnadottir S., Gudjonsson J.E., Aphale A., Sigmarsdottir A.A., Gunnarsson S.I., et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 159 (2008) 342-350
38. Wang Y., Chen J., Zhao Y., Geng L., Song F., and Chen H.D. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 158 (2008) 1134-1135
39. Chen Y.J., Wu C.Y., Shen J.L., Chu S.Y., Chen C.K., Chen C.M., et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 144 (2008) 12
40. Unni E., Kittrell F.S., Singh U., and Sinha R. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 6 (2004) R586-R592
41. Mason C.K., McFarlane S., Johnston P.G., Crowe P., Erwin P.J., and Domostoj M.M. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther 7 (2008) 548-558
42. Kapoor S. Inhibition of osteopontin dependent carcinogenesis. J Cancer Res Clin Oncol 134 (2008) 927-928
43. de Las Fuentes L., Gu C.C., Mathews S.J., Reagan J.L., Ruthmann N.P., Waggoner A.D., et al. Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness. J Am Soc Echocardiogr 21 (2008) 954-960
44. Brenner D., Labreuche J., Touboul P.J., Schmidt-Petersen K., Poirier O., Perret C., et al. Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke 37 (2006) 1691-1696